Jeremy C. Durack

Memorial Sloan Kettering Cancer Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Stephen B. Solomon

Memorial Sloan Kettering Cancer Center

131

Michael J. Morris

National Cancer Institute

Howard I. Scher

Memorial Sloan Kettering Cancer Center

Majid Maybody

Memorial Sloan Kettering Cancer Center

Jonathan Coleman

Memorial Sloan Kettering Cancer Center

Heather L. McArthur

The University of Texas Southwestern Medical Center

Nikolaus Schultz

Memorial Sloan Kettering Cancer Center

Wassim Abida

Memorial Sloan Kettering Cancer Center

Joseph P. Erinjeri

Memorial Sloan Kettering Cancer Center

Govindarajan Srimathveeravalli

University of Massachusetts Amherst

Cooperative Institutions

Memorial Sloan Kettering Cancer Center

415

Society of Interventional Radiology

257

Cornell University

251

Kettering University

196

New York Proton Center

104

Weill Cornell Medicine

University of California, San Francisco

Harvard University

Johns Hopkins University

American College

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Goutam Chakraborty Subhiksha Nandakumar Rahim Hirani Bastien Nguyen Konrad H. Stopsack

Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

10.1158/1078-0432.22487544

Cite

Citations (0)

Forthcoming Articles

Journal of Vascular and Interventional Radiology (2023)

Matthias Stechele Moritz Wildgruber Aurelia Markezana Sophia K€ Astle Elif Öcal

10.1016/s1051-0443(23)00306-8

Cite

Citations (0)

Supplementary Figures S1-4 from A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Neeta Pandit‐Taskar Joseph A. O’Donoghue Jeremy C. Durack Serge K. Lyashchenko Sarah M. Cheal

Supplementary Figures S1-4. Figure S1. 89Zr-J591 versus bone scan comparison of lesion positivity. Figure S2. Patient with metastatic prostate cancer (PSA of 10.1) with 89Zr-J591+ lesions that were not seen on MDP. Figure S3. Patient with metastatic prostate cancer (PSA of 0.62). Figure S4. Uniform prior distribution.

10.1158/1078-0432.22461830.v1

Cite

Citations (0)

Supplementary Table S1 from A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Neeta Pandit‐Taskar Joseph A. O’Donoghue Jeremy C. Durack Serge K. Lyashchenko Sarah M. Cheal

Supplementary Table S1. Patient demographics

Table (database)

10.1158/1078-0432.22461827

Cite

Citations (0)

Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Goutam Chakraborty Subhiksha Nandakumar Rahim Hirani Bastien Nguyen Konrad H. Stopsack

Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

10.1158/1078-0432.22487538.v1

Cite

Citations (0)

Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Goutam Chakraborty Subhiksha Nandakumar Rahim Hirani Bastien Nguyen Konrad H. Stopsack

Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

10.1158/1078-0432.22487529.v1

Cite

Citations (0)

Supplementary Table from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Goutam Chakraborty Subhiksha Nandakumar Rahim Hirani Bastien Nguyen Konrad H. Stopsack

Supplementary Table from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Table (database)

10.1158/1078-0432.22487517.v1

Cite

Citations (0)

Mandated Imaging Appropriate Use Criteria

Annals of Internal Medicine (2019)

Keith Hentel Andrew Menard John Mongan Jeremy C. Durack Ali S. Raja

Letters5 November 2019Mandated Imaging Appropriate Use CriteriaKeith D. Hentel, MD, MS, Andrew Menard, JD, John Mongan, MD, Jeremy C. Durack, MD, Ali S. Raja, MD, MBA, MPH, and Ramin Khorasani, MD, MPHKeith D. Hentel, MD, MSWeill Cornell Medicine, New York, New York (K.D.H.)Search for more papers by this author, Andrew Menard, JDJohns Hopkins Medicine, Baltimore, Maryland (A.M.)Search for more papers by this author, John Mongan, MDUniversity of California, San Francisco, San Francisco, California (J.M.)Search for more papers by this author, Jeremy C. Durack, MDMemorial Sloan Kettering Cancer Center, New York, New York (J.C.D.)Search for more papers by this author, Ali S. Raja, MD, MBA, MPHMassachusetts General Hospital, Boston, Massachusetts (A.S.R.)Search for more papers by this author, and Ramin Khorasani, MD, MPHBrigham and Women's Hospital, Boston, Massachusetts (R.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0532 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Mitchell identifies 1 risk of the upcoming Appropriate Use Criteria Program. A qualified decision-support mechanism—even when integrated into the ordering workflow of an electronic health record (EHR)—may be constructed so that the path of least resistance for the ordering provider encourages entry of information that does not optimally reflect the patient's condition or, worse, contradicts the patient's true presentation. For example, the CDS may present a short list of indications without an easy way to include additional data. Addressing erroneous data entry to avoid onerous interaction with the CDS mechanism is challenging, particularly if the ordering providers ...Reference1. Lacson R, Laroya R, Wang A, et al. Integrity of clinical information in computerized order requisitions for diagnostic imaging. J Am Med Inform Assoc. 2018;25:1651-6. [PMID: 30517649] doi:10.1093/jamia/ocy133 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Weill Cornell Medicine, New York, New York (K.D.H.)Johns Hopkins Medicine, Baltimore, Maryland (A.M.)University of California, San Francisco, San Francisco, California (J.M.)Memorial Sloan Kettering Cancer Center, New York, New York (J.C.D.)Massachusetts General Hospital, Boston, Massachusetts (A.S.R.)Brigham and Women's Hospital, Boston, Massachusetts (R.K.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-0287. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoWhat Physicians and Health Organizations Should Know About Mandated Imaging Appropriate Use Criteria Keith D. Hentel , Andrew Menard , John Mongan , Jeremy C. Durack , Pamela T. Johnson , Ali S. Raja , and Ramin Khorasani Mandated Imaging Appropriate Use Criteria David M. Mitchell Metrics 5 November 2019Volume 171, Issue 9Page: 682-683KeywordsChartsComputed axial tomographyDiagnostic radiologyDisclosureElectronic medical recordsInformation technologyMagnetic resonance imagingMotivationPatientsSpine ePublished: 5 November 2019 Issue Published: 5 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...

Presentation (obstetrics)

10.7326/l19-0532

Cite

Citations (0)

Supplementary Table 1 from Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

David B. Page Jianda Yuan David Redmond Y Hanna Wen Jeremy C. Durack

Supplementary Table 1: TCRB sequencing sample IDs

Table (database)

10.1158/2326-6066.22537895

Cite

Citations (0)

Macrophage-secreted TGF-β₁ contributes to fibroblast activation and ureteral stricture after ablation injury

AJP Renal Physiology (2019)

Eisuke Ueshima Masashi Fujimori Hiroshi Kodama Diane Felsen Jie Chen

Iatrogenic injury to the healthy ureter during ureteroscope-guided ablation of malignant or nonmalignant disease can result in ureteral stricture. Transforming growth factor (TGF)-β

Pirfenidone

10.1152/ajprenal.00260.2018

Cite

Citations (91)